Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672 · Terminated

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1 can help people with type 2 diabetes who have also undergone bariatric surgery achieve partial remission of their diabetes.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 3 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-08 · est. completion 2022-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04624672 ↗

Description as written by the study sponsor.

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

Treatments tested

Semaglutide (1 Mg Dose) also known as semaglutide Drug

Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
Placebo Drug

Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery

Main thing measured	RATE OF PARTIAL REMISSION OF DIABETES
Sponsor	Geisinger Clinic
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04624672 ↗